Abstract
Background: Cancer is one of the severest diseases in the world, and lung cancer is one of the five common cancers causing thousands of deaths every year. Moreover, most of the lung cancer patients die because of bone metastasis.
Methods: This research was conducted with the aim of developing novel nanoparticles (NPs) of docetaxel (DTX) loaded bovine serum albumin (BSA) conjugated docosahexaenoic acid (DHA) using an emulsion/solvent evaporation method for inhibiting lung cancer metastasis to bone. The in vitro drug release of the DTX-DHA-BSA-NPs showed that the nanoparticles released in a sustained and controlled manner contributed to continual fight against cancer cells. The study results revealed that the DTX-DHA-BSA-NPs had higher antitumor efficacy in comparison with the DTXBSA- NPs or DTX in vitro. Result: The study results also showed that the DTX-DHA-BSA-NPs had higher inhibiting efficacy of lung cancer metastasis to bone in comparison with the DTX-BSA-NPs or DTX in vivo. Furthermore, the mean survival time was longer with DTX-DHA-BSA-NPs (24.40 d) than that of DTX (20.95 d). In consideration of these results, the DTXDHA- BSA-NPs may hold potential for bone metastasis of lung cancer treatment.Keywords: Bone metastasis, lung cancer, docosahexaenoic acid, docetaxel, nanoparticles.
Anti-Cancer Agents in Medicinal Chemistry
Title:Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone
Volume: 17 Issue: 4
Author(s): Yuangang Zu, Yan Hu, Xueying Yu and Shougang Jiang*
Affiliation:
- Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, Harbin,China
Keywords: Bone metastasis, lung cancer, docosahexaenoic acid, docetaxel, nanoparticles.
Abstract: Background: Cancer is one of the severest diseases in the world, and lung cancer is one of the five common cancers causing thousands of deaths every year. Moreover, most of the lung cancer patients die because of bone metastasis.
Methods: This research was conducted with the aim of developing novel nanoparticles (NPs) of docetaxel (DTX) loaded bovine serum albumin (BSA) conjugated docosahexaenoic acid (DHA) using an emulsion/solvent evaporation method for inhibiting lung cancer metastasis to bone. The in vitro drug release of the DTX-DHA-BSA-NPs showed that the nanoparticles released in a sustained and controlled manner contributed to continual fight against cancer cells. The study results revealed that the DTX-DHA-BSA-NPs had higher antitumor efficacy in comparison with the DTXBSA- NPs or DTX in vitro. Result: The study results also showed that the DTX-DHA-BSA-NPs had higher inhibiting efficacy of lung cancer metastasis to bone in comparison with the DTX-BSA-NPs or DTX in vivo. Furthermore, the mean survival time was longer with DTX-DHA-BSA-NPs (24.40 d) than that of DTX (20.95 d). In consideration of these results, the DTXDHA- BSA-NPs may hold potential for bone metastasis of lung cancer treatment.Export Options
About this article
Cite this article as:
Zu Yuangang, Hu Yan, Yu Xueying and Jiang Shougang*, Docetaxel-loaded Bovine Serum Albumin Nanoparticles Conjugated Docosahexaenoic Acid for Inhibiting Lung Cancer Metastasis to Bone, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (4) . https://dx.doi.org/10.2174/1871520616666160817143656
DOI https://dx.doi.org/10.2174/1871520616666160817143656 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Current Cancer Drug Targets A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Atypical PKCι as Target for Glioblastoma Therapy
Current Cancer Drug Targets Differentiation-Inducing Therapy for Solid Tumors
Current Pharmaceutical Design Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry Pleiotropic Functions of Rho GTPase Signaling: A Trojan Horse or Achilles Heel for Breast Cancer Treatment?
Current Drug Targets Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs
Letters in Drug Design & Discovery Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Regulation Mechanism of MicroRNAs in Non-Small Cell Lung Cancer
Current Pharmaceutical Design Transient Abnormal Myelopoiesis in Down’s Syndrome - A Diagnostic Dilemma
Applied Clinical Research, Clinical Trials and Regulatory Affairs Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course
Current Cancer Therapy Reviews Role of Apoptosis and Apoptosis-Related Genes in Cellular Response and Antitumor Efficacy of Anthracyclines
Current Medicinal Chemistry Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Nanomedicines as Cancer Therapeutics: Current Status
Current Cancer Drug Targets Current State of the Art for Survival Prediction in Cancer Using Data Mining Techniques
Current Bioinformatics Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets